CRBP (Corbus Pharmaceuticals Holdings) E10: $-23.06 (As of Mar. 2026)


CRBP Corbus Pharmaceuticals Holdings Inc CRBP
31 GF Score
Price $8.73
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings E10?

Corbus Pharmaceuticals Holdings CRBP +0.46% 31 E10 is $-23.06 as of Mar. 2026. GuruFocus rates CRBP with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Corbus Pharmaceuticals Holdings's adjusted earnings per share data for the three months ended in Mar. 2026 was $-1.230. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-23.06 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-29), Corbus Pharmaceuticals Holdings's current stock price is $8.73. Corbus Pharmaceuticals Holdings's E10 for the quarter that ended in Mar. 2026 was $-23.06. Corbus Pharmaceuticals Holdings's Shiller PE Ratio of today is .


Corbus Pharmaceuticals Holdings  (NAS:CRBP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Corbus Pharmaceuticals Holdings E10 Related Terms


Corbus Pharmaceuticals Holdings E10 Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings E10 Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -22.15 -22.77 -22.83

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.97 -22.90 -23.01 -22.83 -23.06

CRBP vs PRQR, NRXP, CRBU: E10 Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Shiller PE Ratio falls into.


CRBP
31GF Score
Corbus Pharmaceuticals Holdings Inc CRBP
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Corbus Pharmaceuticals Holdings's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.23/330.2130*330.2130
=-1.230

Current CPI (Mar. 2026) = 330.2130.

Corbus Pharmaceuticals Holdings Quarterly Data

per share eps CPI Adj_EPS
201606 -3.300 241.018 -4.521
201609 -3.600 241.428 -4.924
201612 -5.400 241.432 -7.386
201703 -4.800 243.801 -6.501
201706 -4.500 244.955 -6.066
201709 -4.200 246.819 -5.619
201712 -6.300 246.524 -8.439
201803 -6.300 249.554 -8.336
201806 -6.300 251.989 -8.256
201809 -7.800 252.439 -10.203
201812 -9.000 251.233 -11.829
201903 -12.900 254.202 -16.757
201906 0.900 256.143 1.160
201909 -9.600 256.759 -12.346
201912 -12.300 256.974 -15.806
202003 -12.900 258.115 -16.503
202006 -15.600 257.797 -19.982
202009 -12.900 260.280 -16.366
202012 -3.000 260.474 -3.803
202103 -4.200 264.877 -5.236
202106 -4.500 271.696 -5.469
202109 -0.600 274.310 -0.722
202112 -2.400 278.802 -2.843
202203 -2.260 287.504 -2.596
202206 -3.180 296.311 -3.544
202209 -2.110 296.808 -2.347
202212 -2.610 296.797 -2.904
202303 -4.240 301.836 -4.639
202306 -2.050 305.109 -2.219
202309 -2.270 307.789 -2.435
202312 -1.790 306.746 -1.927
202403 -0.830 312.332 -0.878
202406 -0.900 314.175 -0.946
202409 -1.150 315.301 -1.204
202412 -0.780 315.605 -0.816
202503 -1.390 319.799 -1.435
202506 -1.440 322.561 -1.474
202509 -1.900 324.800 -1.932
202512 -1.250 324.054 -1.274
202603 -1.230 330.213 -1.230

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-23.06 mean?
Corbus Pharmaceuticals Holdings (CRBP) has a E10 of $-23.06 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' E10 too high?
Corbus Pharmaceuticals Holdings' current E10 is $-23.06. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' E10 compare to PRQR and NRXP?
Corbus Pharmaceuticals Holdings' E10 of $-23.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current E10 is $-23.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Corbus Pharmaceuticals Holdings (CRBP) has a current E10 of $-23.06. The current E10 is $-23.06. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (CRBP), the current E10 is $-23.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges 0SZI:UK3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score

Get the complete analysis for CRBP

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.73
Price